Company: HCTI
Filing Date: 2025-11-19
Form Type: 424B5
Source: 0001213900-25-112544
Chunk: 10

Company: Healthcare Triangle, Inc.
Filing Date: 2025-11-19
Form: 424B5
Chunk 10
---
binding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. |

We have taken advantage of certain reduced reporting requirements in this prospectus. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold stock. An emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected to avail ourselves of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the dates on which adoption of such standards is required for other public reporting companies. We are also a “smaller reporting company” as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), and have elected to take advantage of certain of the scaled disclosure available for smaller reporting companies.

<div align='center'>S-3</div>

Recent Developments

Annual Meeting.On November 7, 2025,
at the virtual annual meeting of shareholders (the “Annual Meeting”), our shareholders: (i) re-elected our four (4)
directors to serve a one (1) year term; and (ii) ratified the appointment SRCO Professional Corporation, Chartered Professional Accountants
(“SRCO”) as the Company’s independent registered public accounting firm for the year ending December 31, 2025.

Warrant Inducement. On October 2,
2025, we entered into a warrant inducement letter (the “Inducement Agreement”) with certain holders (the “Holders”)
of the Company’s warrants to purchase shares of our common stock, issued in a private placement offering that closed on February
28, 2025 (the “PIPE Warrants”). Pursuant to the Inducement Agreement, the Holders of the PIPE Warrants agreed to exercise
for cash the PIPE Warrants to purchase an aggregate of up to 1,429,528 shares of our common stock, at an exercise price of $2.00 per share,
which was reduced from $20.916 per share. The transactions contemplated by the Inducement Agreement (the “Warrant Inducement”)
were consummated on October 2, 2025, October 3,